Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening

Food and Chemical Toxicology

Volumn 49, Issue 2, 2011, Pages 441-449

  Anadón, Arturo ^a   Suárez, Frank H ^a   Martínez, María A ^a   Castellano, Víctor ^a   Martínez, Marta ^a   Ares, Irma ^a   Ramos, Eva ^a   Gamboa, Felipe ^a   Martínez Larrañaga, María R ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Chickens for fattening; Difloxacin; Plasma and tissue depletion; Sarafloxacin; Withdrawal time

Indexed keywords

DIFLOXACIN; NORDIFLOXACIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL HUSBANDRY; ANIMAL PRODUCT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHICKEN MEAT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; KIDNEY PARENCHYMA; LIVER LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE LEVEL; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RESIDUE ANALYSIS; SINGLE DRUG DOSE; SKIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIA; CHICKENS; CIPROFLOXACIN; DRUG RESIDUES; DRUG RESISTANCE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

ANIMALIA; GALLUS GALLUS;

EID: 78951489731     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.11.021     Document Type: Article

References (57)

1. Abd El-Aty A.M., Goudah A., Ismail M., Shimoda M. Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. Vet. Res. Commun. 2005, 29:297-304.
2. Abo-El-Sooud K., Goudah A. Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). Vet. J. 2008, 179:282-286.
3. Adams A.R., Haines G.R., Brown M.P., Gronwall R., Merritt K. Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. Can. J. Vet. Res. 2005, 69:229-235.
4. Anderson A.D., Nelson J.M., Rossiter S., Angulo F.J. Public health consequences of use of antimicrobial agents in food animals in the United States. Microb. Drug Resist. 2003, 9(4):373-379.
5. Angulo F.J., Johnson K.R., Tauxe R.V., Cohen M.L. Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella: implications for the use of fluoroquinolones in food animals. Microb. Drug Resist. 2000, 6(1):77-83.
6. Boxenbaum H. Pharmacokinetics tricks and traps: flip-flop models. J. Pharm. Pharm. Sci. 1998, 1(3):90-91.
7. EMEA (The European Agency for the Evaluation of Medicinal Products), 1998. Guideline on Validation of Analytical Procedures: Methodology (VICH GL2). CVMP/VICH/591/98-FINAL, pp. 1-10.
8. EMEA (The European Agency for the Evaluation of Medicinal Products), 2002a. Committee for Veterinary Medicinal Products. Summary Report on Difloxacin (Extension to all food producing species). EMEA/MRL/819/02-FINAL, pp. 1-2.
9. EMEA (The European Agency for the Evaluation of Medicinal Products), 2002b. Updated Application Software relating to Note for Guidance on Approach towards Harmonisation of Withdrawal Periods for Meat. EMEA/CVMP/563/02, p. 1.
10. Bansal M.B., Thadepalli H. Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro. Antimicrob. Agents Chemother. 1987, 31:619-621.
11. Barry A.L., Thornsberry C., Jones R.N. In vitro evaluation of A-56619 and A-56620, two new quinolones. Antimicrob. Agents Chemother. 1986, 29:40-43.
12. Chu D.T.W., Fernandes P.B. Sctructure-activity relationships of the fluoroquinolones. Antimicrob. Agents Chemother. 1989, 33:131-135.
13. Chu D.T.W., Granneman G.R., Fernandes P.B. ABBOTT-56619. Drugs Future 1985, 10:543-545.
14. Cozzarelli N.R. DNA gyrase and the supercoiling of DNA. Science 1980, 207:953-960.
15. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infec. Dis. 1998, 26:1-12.
16. Dalla Costa T., Derendorf H. AUIC - a general target for the optimisation of dosing regimens of antibiotics?. Ann. Pharmacother. 1996, 30:1024-1031.
17. Ding H.Z., Yang G.X., Huang X.H., Chen Z.L., Zeng Z.L. Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. J. Vet. Pharmacol. Ther. 2008, 31:200-204.
18. Drlica K. Biology of bacterial deoxyribonucleic acid topoisomerases. Microbiol. Rev. 1984, 48:273-289.
19. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997, 61:377-392.
20. Drusano G.L., Johnson D.E., Rosen M., Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 1993, 37:483-490.
21. Dudley M.N. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am. J. Med. 1991, 91:45-50. (Suppl.1).
22. Eliopoulos G.M., Moellering A.E., Reiszner E., Moellering Jr.R.C. In vitro activity of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob. Agents Chemother. 1985, 28:514-520.
23. Fernandes P.B., Chu D.T., Bower R.R., Jarvis K.P., Ramer N.R., Shipkowitz N. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob. Agents Chemother. 1986, 29:201-208.
24. Fernández-Varón E., Cárceles C.M., Marín P., Martos N., Escudero E., Ayala I. Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. Am. J. Vet. Res. 2006, 67:1076-1081.
25. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., Schentag J.J. Pharmacodynamics of IV ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 1993, 37:1073-1081.
26. Frazier D.L., Thompson L., Trettien A., Evans E.I. Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin and difloxacin in dogs. J. Vet. Pharmacol. Ther. 2000, 23:293-302.
27. Gellert M. DNA topoisomerases. Annu. Rev. Biochem. 1981, 50:879-910.
28. Gerchman I., Lysnyansky I., Perk S., Levishn S. In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkeys. Vet. Microbiol. 2008, 131:266-276.
29. Granneman G.R., Snyder K.M., Shu V.S. Difloxacin metabolism and pharmacokinetics in humans after single oral doses. Antimicrob. Agents Chemother. 1986, 26:689-693.
30. Hardee G.E., Baggot J.D. Development and formulations of veterinary dosage forms. Drugs in the Pharmaceutical Sciences 1998, 100-103. Marcel Dekker Inc, New York. second ed. G.E. Hardee, J.D. Baggot (Eds.).
31. Heinen E. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. J. Vet. Pharmacol. Ther. 2002, 25:1-5.
32. Hooper D.C., Wolfson J.S. Mechanism of quinolone action and bacterial killing. Quinolone Antimicrobial Agents 1993, 53-75. American Society for Microbiology, Washington, DC. second ed. D.C. Hooper, J.S. Wolfson (Eds.).
33. Humphrey T.J., Jorgensen F., Frost J.A., Wadda H., Domingue G., Elviss N.C., Griggs D.J., Piddock L.J. Prevalence and subtypes of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and after treatment with fluoroquinolones. Antimicrob. Agents Chemother 2005, 49(2):690-698.
34. Hyatt J.M., McKinnon P.S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 1995, 28:143-160.
35. Inui T., Taira T., Matsushita T., Endo T. Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. Xenobiotica 1998, 28:887-893.
36. Ismail M. Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. Vet. Res. Commun. 2007, 31:467-476.
37. Kenny G.E., Hooton T.M., Roberts M.C., Cartwright F.D., Hoy J. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob. Agents Chemother. 1989, 33:103-107.
38. Lacy M.K., Lu W., Xu X., Tessier P.R., Nicolau D.P., Quintiliani R., Nightingale C.H. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob, Agents Chemother. 1999, 43:672-677.
39. Lees P., Aliabadi F.S. Rational dosing of antimicrobial drugs: animals versus humans. Int. J. Antimicrob. Agents 2002, 19:269-284.
40. Lister P.D., Sanders C.C. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 1999, 43:79-86.
41. Lister P.D., Sanders C.C. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob, Agents Chemother. 1999, 43:1118-1123.
42. Lode H., Borner K., Koeppe P. Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 1998, 27:33-39.
43. Madaras-Kelly K.J., Ostergaard B.E., Baeker Hovde L., Rotschafer J.C. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 1996, 40:627-632.
44. Marín P., Escudero E., Fernández-Varón E., Cárceles C.M. Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneus and intramuscular administration to lactating goats. J. Vet. Pharmacol. Ther. 2007, 30:74-79.
45. Marín P., Fernández-Varón E., Escudero E., Cárceles C.M. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. Res. Vet. Sci. 2007, 83:234-238.
46. Ramos M., Aranda A., García E., Reuvers T., Hooghuis H. Simple and sensitive determination of five quinolones in food by liquid chromatography with fluorescence detection. J. Chromatogr. B 2003, 789:373-381.
47. Smith B.R., Lefrock J.L., Donato J.B., Joseph W.S., Weber S.J. In vitro activity of A-56619 and A-56620, two new aryl-fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother. 1986, 29:355-358.
48. Stamm J.M., Hanson C.W., Chu D.T.W., Bailer R., Vojtko C., Fernandes P.B. In vitro evaluation of ABBOTT-56619 (difloxacin) and ABBOTT-56620: new aryl-fluoroquinolones. Antimicrob. Agents Chemother. 1986, 29:193-200.
49. Suárez F.H., Gamboa F., Nieto I., Martínez M.A., Castellano V., Martínez-Larrañaga M.R., Anadón A. Disposition of difloxacin and its metabolite sarafloxacin in healthy chickens. 11th International EAVPT Congress. Leipzig (Germany), July 12-16. Abstract in J. Vet. Pharmacol. Ther. 2009, 32(Suppl. 1):145.
50. Sukul P., Lamshoft M., Kusari S., Zünlkr S., Spiteller M. Metabolism and excretion kinetics of 14C-labeled and non-labeled difloxacin in pigs after oral administration, and antimicrobial activity of manure containing difloxacin and its metabolites. Environ. Res. 2009, 109(3):225-231.
51. Toutain P.L., Del Castillo J.R.E., Bousquet-Mélou A. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res. Vet. Sci. 2002, 73:105-114.
52. Wagner J.G. Fundamentals of Clinical Pharmacokinetics 1975, Drug Intelligence Publications, Hamilton, Illinois. first ed.
53. Wagner J.G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J. Pharmacokinet. Biopharm. 1976, 4:443-467.
54. Walker R.D. The use of fluoroquinolones for companion animal antimicrobial therapy. Aust. Vet. J. 2000, 78:84-90.
55. Wolfson J.S., Hooper D.C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother. 1985, 28:581-586.
56. Wright D.H., Brown G.H., Peterson M.L., Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 2000, 46:669-683.
57. Yamaoka K., Nakagawa T., Uno T. Application of akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 1978, 6:165-175.